Skip to main content

Rosetta Genomics Licenses Nanogen's MGB Probes for Use with Upcoming miRNA Diagnostics

NEW YORK (GenomeWeb News) - Rosetta Genomics said today that it has licensed Nanogen’s MGB Probe technology for use with a line of microRNA biomarker-based diagnostic tests that it plans to launch in 2008.
 
Rosetta plans to use the MGB, or minor groove binder, probes to develop a line of real-time PCR-based diagnostic tests.
 
Rosetta said it expects to launch three tests in 2008: one that will differentiate squamous from non squamous lung cancers; another to differentiate mesothelioma from lung adenocarcinoma; and another to identify the origin of tumors in cancer cases where this is not known. The company said clinicians cannot identify the origin of metastases in between three and five percent of all cancer patients.
 
Financial terms of the licensing agreement with Nanogen were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.